Cochlear reaffirmed fiscal 2027 guidance for low-single-digit constant-currency revenue growth and AUD 330 million to AUD 350 million in underlying net profit. Developed-market implant volumes grew at a mid-single-digit rate from July to October, in line with management's expectations.
There are signs Cochlear is looking to expand beyond the hearing market with the investment in Nyxoah, a company focused on hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.
Bears
Growth in the cochlear implant market is becoming more costly to achieve, limiting the potential upside to earnings.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.